Pasritamig——首创新药靶向人激肽释放酶2的双特异性T细胞衔接器治疗转移性去势抵抗性前列腺癌的I期研究
这项I期研究评估了靶向人激肽释放酶2(KLK2)的首创双特异性T细胞衔接器pasritamig在转移性去势抵抗性前列腺癌患者中的安全性和推荐II期剂量(RP2D)。174例参与者接受治疗,RP2D确定为第1天3.5 mg、第8天18 mg、第15天300 mg,之后300 mg静脉给药每6周一次;RP2D安全性人群(n=45)中所有治疗相关不良事件均为1级或2级,细胞因子释放综合征(CRS)发生率为8.9%且均为1级。RP2D疗效人群(n=33)中位影像学无进展生存期为7.85个月(95%CI 2.89至不可估计),42.4%的参与者前列腺特异性抗原较基线下降≥50%。
要点
- pasritamig在转移性去势抵抗性前列腺癌中显示出有利的安全性特征,CRS发生率低。
- RP2D为第1天3.5 mg、第8天18 mg、第15天300 mg,之后300 mg静脉给药每6周一次。
- RP2D疗效人群中42.4%的参与者前列腺特异性抗原较基线下降≥50%。
核心结论
- pasritamig显示出有利的安全性特征,CRS发生率非常低,可在门诊环境中安全给药。
- 初步抗肿瘤活性证明了KLK2作为前列腺癌靶点的概念验证,值得进一步开发pasritamig。
研究设计与样本
- I期试验,纳入转移性去势抵抗性前列腺癌且≥1线既往治疗的患者。
- pasritamig皮下给药从0.5 mg递增至2,000 mg,静脉给药从150 mg递增至900 mg,给药频率从每周一次至每6周一次,采用不同的逐步递增给药方案。
- 主要目标为确定安全性和推荐II期剂量(RP2D);次要目标包括初步评估抗肿瘤活性。
- 共174例参与者接受pasritamig治疗,既往系统性治疗中位线数为4线。
主要发现
- 治疗相关不良事件(TRAE)发生于174例中的144例(82.8%),174例中17例(9.8%)发生≥3级TRAE。
- RP2D安全性人群(n=45)中最常见的TRAE为输液相关反应(11/45,24.4%)、疲乏(7/45,15.6%)、细胞因子释放综合征(CRS;4/45,8.9%,均为1级)和脂肪酶升高(4/45,8.9%);所有TRAE均为1级或2级。
- RP2D疗效人群(n=33)中位影像学无进展生存期为7.85个月(95%CI 2.89至不可估计)。
- RP2D疗效人群(n=33)中33例中的14例(42.4%)前列腺特异性抗原较基线下降≥50%。
关键数值与推荐
- RP2D确定为第1天3.5 mg、第8天18 mg、第15天300 mg,之后300 mg静脉给药每6周一次。
临床怎么用
- pasritamig可在门诊环境中安全给药。
- 原文结论指出值得进一步开发pasritamig。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We report phase I trial results for pasritamig, a first-in-class, T-cell-engaging bispecific antibody targeting human kallikrein 2 (KLK2) expressed on the surface of prostate cancer (PC) cells. METHODS: Participants had metastatic castration-resistant PC and ≥1 prior therapy. Pasritamig was escalated from 0.5 mg to 2,000 mg for subcutaneous administration and from 150 mg to 900 mg for intravenous (IV) administration at dosing frequencies ranging from once every week to once every 6 weeks with different step-up dosing schedules. The primary objectives were to determine safety and the recommended phase II dose (RP2D) of pasritamig. Secondary objectives included preliminary assessment of antitumor activity. RESULTS: One hundred seventy-four participants received pasritamig, with a median of 4 prior lines of systemic therapy. Treatment-related adverse events (TRAEs) occurred in 144 of 174 (82.8%) participants, with 17 of 174 (9.8%) experiencing grade ≥3 TRAEs. The RP2D was determined to be 3.5 mg (day 1), 18 mg (day 8), 300 mg (day 15), and then 300 mg IV once every 6 weeks. In the RP2D safety population (n = 45), infusion-related reactions (11/45, 24.4%), fatigue (7/45, 15.6%), cytokine release syndrome (CRS; 4/45, 8.9%, all grade 1), and lipase increase (4/45, 8.9%) were the most frequent TRAEs; all were grade 1 or 2. In the RP2D efficacy population (n = 33), median radiographic progression-free survival was 7.85 (95% CI, 2.89 to not estimable) months, and 14 of 33 (42.4%) participants achieved a ≥50% decrease from baseline in prostate-specific antigen. CONCLUSION: Pasritamig demonstrated a favorable safety profile with very low rates of CRS and could be safely administered in an outpatient setting. Preliminary antitumor activity demonstrated proof of concept for KLK2 as a target in PC, warranting further development of pasritamig.
引用
- Stein MN, Vinceneux A, Robbrecht D, et al. Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. J Clin Oncol. 2025. PMID: 40450573. doi:10.1200/JCO-25-00678
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。